JUPITER, Fla., May 7, 2013 – Dyadic International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June. Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm’s Investment Bank.
“Danai has significant financial and operational experience in the renewable energy and bio-based chemical space, and will be a tremendous asset to Dyadic,” said Mark Emalfarb, Dyadic’s President and Chief Executive Officer. “As EVP and COO, Danai will play a key role in driving our business development and licensing efforts, as well as corporate strategic planning and operational improvements across the globe.”
“As a long-time advisor to Dyadic, I am intimately familiar with the Company and thrilled to have the opportunity to join the team” said Brooks. “Dyadic continues to compete with larger industrial enzyme companies using its game-changing C1 enzyme expression platform. Together, we will continue to build commercial momentum through enzyme sales and strategic partnerships across a wide range of sectors including cellulosic biofuels, biopharmaceuticals and industrial applications. We look forward to introducing new C1-based products to the many industries and companies that can benefit from C1’s ability to produce enzymes and other proteins with class leading performance.”
While at J.P. Morgan, Brooks advised clients across a broad spectrum of sectors, including chemicals, renewable energy and industrials. He has held senior operational, engineering and manufacturing positions with Dell Inc., Mars Inc. and Ford Motor Company. He received a B.S. in Industrial Engineering and Master of Engineering from Cornell University, a Master of Engineering Management from Northwestern University and an MBA from Northwestern’s Kellogg School of Management.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic’s website atwww.dyadic.com.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Dyadic International, Inc. Michael J. Faby
Chief Financial Officer Phone: (561) 743-8333 Email: email@example.com